Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cardinal Health Inc (CAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cardinal Health Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Cardinal Health Inc trades at $238.18 (market cap $56.14B). The key difference: Cardinal Health Inc is far larger — about 12.5× ACADIA Pharmaceuticals Inc.'s market cap, and Cardinal Health Inc pays a 0.85% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CAH | |
|---|---|---|
Market Cap | $4.49B | $56.14B |
Sector | Health | Health |
52-Week High | $28.06 | $239.71 |
52-Week Low | $20.06 | $146.04 |
Enterprise Value | $3.69B | $61.12B |
Dividend Yield | — | 0.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Cardinal Health (CAH) trades at $239.71, up 0.32% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats, including Q1 2026 EPS of $3.17 beating estimates of $2.79. Revenue reached $222.58B in 2025 with net income of $1.56B. Technical indicators are bullish, with the current price above key support levels. Analysts maintain a positive outlook with a consensus price target of $243.33.
CAH presents a compelling investment case driven by earnings growth and defensive healthcare distribution. However, risks include high debt levels, thin profit margins, and competitive pressures. The stock's valuation at a P/E of 36.26 may limit upside if growth moderates. Overall, the bullish analyst consensus and operational strength support a positive medium-term view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
